RLMD logo

Relmada Therapeutics (RLMD) EBITDA

Annual EBITDA

-$103.70 M
+$57.55 M+35.69%

December 31, 2023


Summary


Performance

RLMD EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

High & Low

Earnings dates

OtherRLMDprofitabilitymetrics:

Quarterly EBITDA

-$23.01 M
-$4.19 M-22.26%

September 30, 2024


Summary


Performance

RLMD Quarterly EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

High & Low

Earnings dates

OtherRLMDprofitabilitymetrics:

TTM EBITDA

-$91.64 M
-$316.20 K-0.35%

September 30, 2024


Summary


Performance

RLMD TTM EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

High & Low

Earnings dates

OtherRLMDprofitabilitymetrics:

EBITDA Formula

EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization

RLMD EBITDA Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year+35.7%-0.1%+7.0%
3 y3 years-70.5%+46.1%+18.5%
5 y5 years-715.1%-520.8%-799.2%

RLMD EBITDA Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-yearat high+35.7%-22.3%+49.4%-0.3%+43.2%
5 y5-year-1154.0%+35.7%-520.8%+49.4%-799.2%+43.2%
alltimeall time<-9999.0%+35.7%-521.7%+49.4%-8085.8%+43.2%

Relmada Therapeutics EBITDA History

DateAnnualQuarterlyTTM
Sep 2024
-
-$23.01 M(+22.3%)
-$91.64 M(+0.3%)
Jun 2024
-
-$18.82 M(-18.1%)
-$91.33 M(-7.3%)
Mar 2024
-
-$22.99 M(-14.3%)
-$98.54 M(-5.0%)
Dec 2023
-$103.70 M(-35.7%)
-$26.83 M(+18.2%)
-$103.70 M(-10.3%)
Sep 2023
-
-$22.69 M(-12.8%)
-$115.58 M(-12.2%)
Jun 2023
-
-$26.03 M(-7.6%)
-$131.62 M(-12.9%)
Mar 2023
-
-$28.15 M(-27.3%)
-$151.11 M(-6.3%)
Dec 2022
-$161.25 M(+28.3%)
-$38.70 M(-0.1%)
-$161.25 M(+2.9%)
Sep 2022
-
-$38.74 M(-14.9%)
-$156.73 M(-2.4%)
Jun 2022
-
-$45.51 M(+18.8%)
-$160.65 M(+13.5%)
Mar 2022
-
-$38.30 M(+12.0%)
-$141.60 M(+12.6%)
Dec 2021
-$125.70 M(+106.6%)
-$34.18 M(-19.9%)
-$125.70 M(+11.8%)
Sep 2021
-
-$42.65 M(+61.2%)
-$112.44 M(+29.3%)
Jun 2021
-
-$26.46 M(+18.1%)
-$86.97 M(+18.7%)
Mar 2021
-
-$22.40 M(+7.1%)
-$73.27 M(+20.4%)
Dec 2020
-$60.83 M(+635.7%)
-$20.92 M(+21.8%)
-$60.83 M(+52.4%)
Sep 2020
-
-$17.18 M(+34.7%)
-$39.91 M(+51.0%)
Jun 2020
-
-$12.76 M(+27.9%)
-$26.44 M(+89.0%)
Mar 2020
-
-$9.97 M(+169.1%)
-$13.99 M(+37.2%)
Dec 2019
-$8.27 M(-35.0%)
-
-
Sep 2019
-
-$3.71 M(+1113.2%)
-$10.19 M(+14.6%)
Jun 2019
-$12.72 M(+84.0%)
-$305.50 K(-88.7%)
-$8.90 M(-16.1%)
Mar 2019
-
-$2.70 M(-22.4%)
-$10.60 M(-1.0%)
Dec 2018
-
-$3.48 M(+44.4%)
-$10.71 M(+23.3%)
Sep 2018
-
-$2.41 M(+19.8%)
-$8.68 M(+19.7%)
DateAnnualQuarterlyTTM
Jun 2018
-$6.91 M(-3.1%)
-$2.01 M(-28.2%)
-$7.25 M(+3.5%)
Mar 2018
-
-$2.80 M(+92.6%)
-$7.01 M(+8.4%)
Dec 2017
-
-$1.46 M(+48.5%)
-$6.46 M(-0.9%)
Sep 2017
-
-$980.30 K(-44.4%)
-$6.52 M(-8.6%)
Jun 2017
-$7.13 M(-55.9%)
-$1.76 M(-21.9%)
-$7.13 M(-15.6%)
Mar 2017
-
-$2.26 M(+49.4%)
-$8.45 M(-5.2%)
Dec 2016
-
-$1.51 M(-5.2%)
-$8.91 M(-32.1%)
Sep 2016
-
-$1.60 M(-48.2%)
-$13.12 M(+91.4%)
Jun 2016
-$16.16 M(-5.4%)
-$3.08 M(+13.3%)
-$6.85 M(-16.1%)
Mar 2016
-
-$2.72 M(-52.5%)
-$8.17 M(-18.5%)
Dec 2015
-
-$5.72 M(-222.6%)
-$10.03 M(-973.8%)
Sep 2015
-
$4.67 M(-206.1%)
$1.15 M(-103.4%)
Jun 2015
-$17.09 M(-18.2%)
-$4.40 M(-3.9%)
-$33.35 M(+15.2%)
Mar 2015
-
-$4.58 M(-183.9%)
-$28.95 M(+18.8%)
Dec 2014
-
$5.46 M(-118.3%)
-$24.38 M(-18.3%)
Sep 2014
-
-$29.83 M(>+9900.0%)
-$29.85 M(>+9900.0%)
Jun 2014
-$20.90 M(>+9900.0%)
-
-
Feb 2014
-
-$3000.00(-78.9%)
-$48.80 K(-2.2%)
Nov 2013
-
-$14.20 K(+16.4%)
-$49.90 K(+11.6%)
Aug 2013
-$44.80 K(+282.9%)
-$12.20 K(-37.1%)
-$44.70 K(+8.8%)
May 2013
-
-$19.40 K(+373.2%)
-$41.10 K(+69.8%)
Feb 2013
-
-$4100.00(-54.4%)
-$24.20 K(+19.8%)
Nov 2012
-
-$9000.00(+4.7%)
-$20.20 K(+80.4%)
Aug 2012
-$11.70 K
-$8600.00(+244.0%)
-$11.20 K(+330.8%)
May 2012
-
-$2500.00(+2400.0%)
-$2600.00(+2500.0%)
Feb 2012
-
-$100.00
-$100.00

FAQ

  • What is Relmada Therapeutics annual EBITDA?
  • What is the all time high annual EBITDA for Relmada Therapeutics?
  • What is Relmada Therapeutics annual EBITDA year-on-year change?
  • What is Relmada Therapeutics quarterly EBITDA?
  • What is the all time high quarterly EBITDA for Relmada Therapeutics?
  • What is Relmada Therapeutics quarterly EBITDA year-on-year change?
  • What is Relmada Therapeutics TTM EBITDA?
  • What is the all time high TTM EBITDA for Relmada Therapeutics?
  • What is Relmada Therapeutics TTM EBITDA year-on-year change?

What is Relmada Therapeutics annual EBITDA?

The current annual EBITDA of RLMD is -$103.70 M

What is the all time high annual EBITDA for Relmada Therapeutics?

Relmada Therapeutics all-time high annual EBITDA is -$11.70 K

What is Relmada Therapeutics annual EBITDA year-on-year change?

Over the past year, RLMD annual EBITDA has changed by +$57.55 M (+35.69%)

What is Relmada Therapeutics quarterly EBITDA?

The current quarterly EBITDA of RLMD is -$23.01 M

What is the all time high quarterly EBITDA for Relmada Therapeutics?

Relmada Therapeutics all-time high quarterly EBITDA is $5.46 M

What is Relmada Therapeutics quarterly EBITDA year-on-year change?

Over the past year, RLMD quarterly EBITDA has changed by -$20.90 K (-0.09%)

What is Relmada Therapeutics TTM EBITDA?

The current TTM EBITDA of RLMD is -$91.64 M

What is the all time high TTM EBITDA for Relmada Therapeutics?

Relmada Therapeutics all-time high TTM EBITDA is $1.15 M

What is Relmada Therapeutics TTM EBITDA year-on-year change?

Over the past year, RLMD TTM EBITDA has changed by +$6.89 M (+6.99%)